As several human malignancies including lung cancer express functional PAFR [29,37,38,39], which upon the exposure to pro-oxidative stressors including chemotherapeutic agents and radiation therapy can produce PAF agonists [29,30,31], our first studies verified the pro-oxidative stressors ability of targeted therapies to generate ROS. This evidence concerns the gene PCLAF and lung carcinoma.